In this study, we demonstrate that PU.1, IRF8 and BATF3-mediated cell fate reprogramming of tumor cells into immunogenic cDC1-like cells in situ represents a new immunotherapeutic modality for the treatment of solid tumors. Here, IRF8 is linked to neoplasm.